IMR Press / EJGO / Volume 25 / Issue 2 / pii/2004138

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers

Show Less
1 Department of Obstetrics and Gynecology, Gifu University School of Medicine, Gifu (Japan)
Eur. J. Gynaecol. Oncol. 2004, 25(2), 187–191;
Published: 10 April 2004

Since insulin-like growth factors (IGFs) are known to play critical roles in the development of cancers, we examined the expres­sion of the mRNA and protein of IGF-binding protein (IGFBP) and cognate receptors to assess their possible involvement in gyne­cological malignancy. The specimens were obtained from 46 endometrial, 32 cervical, and 20 ovarian cancers, and 28 normal endometrium. In endometrial cancers, IGFBP-1, -2, -3 and IGF-1 receptor (IGF-JR) mRNAs were detected in 8.7, 89.1, 95.6, and 91.3% of tumors, respectively, and the corresponding proteins in 54.3, 54.3, 95.6, and 91.3% of tumors, respectively. Clinical staging was sig­nificantly related to the expression of IGFBP-1 and -2 proteins. In ovarian cancers, their mRNAs were detected in 10.0, 90.0, 95.0, and 100.0%, and proteins in 15.9, 50.0, 90.0, and 80.0%. In cervical cancers, their mRNAs were detected in 6.3, 90.6, 96.8, and 87.5%, and proteins in 44.4, 18.8, 84.4, and 87.5%. IGF-IR was highly expressed in all specimens. The abnormally balanced co-expression of IGFBPs and high levels of IGF-R in gynecological cancers suggest that IGF signals might be involved in the growth of these tumors.

Endometrial cancer
Cervical cancer
Ovarian cancer
Clinical implication
Back to top